PT Merck Tbk (ISX:MERK) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:MERK PT Merck Tbk ISX:MERK
78 GF Score
Price Rp3,900.00
GF Value Rp4,929.30
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is PT Merck Tbk Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PT Merck Tbk  (ISX:MERK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


PT Merck Tbk Cyclically Adjusted PS Ratio Related Terms


PT Merck Tbk Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for PT Merck Tbk's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Merck Tbk Cyclically Adjusted PS Ratio Chart

PT Merck Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 1.15 1.03 0.87 1.49

PT Merck Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.77 0.89 1.24 1.44

ISX:MERK vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Merck Tbk Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Merck Tbk's Cyclically Adjusted PS Ratio falls into.


ISX:MERK
78GF Score
PT Merck Tbk ISX:MERK
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Merck Tbk Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

PT Merck Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, PT Merck Tbk's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=774.847/137.6954*137.6954
=774.847

Current CPI (Jun. 2026) = 137.6954.

PT Merck Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 607.149 103.212 809.997
201609 511.985 104.142 676.938
201612 507.752 105.222 664.454
201703 706.096 106.476 913.128
201706 647.647 107.722 827.857
201709 651.338 108.020 830.271
201712 576.722 109.017 728.437
201803 315.565 110.097 394.671
201806 343.916 111.085 426.302
201809 369.190 111.135 457.426
201903 364.200 112.829 444.468
201906 342.924 114.730 411.566
201909 404.435 114.905 484.653
201912 550.572 115.486 656.454
202003 362.158 116.252 428.959
202006 269.175 116.630 317.793
202009 350.410 116.397 414.530
202012 482.201 117.318 565.956
202103 565.536 117.840 660.827
202106 565.788 118.184 659.196
202109 623.329 118.262 725.759
202112 621.229 119.516 715.723
202203 673.139 120.948 766.346
202206 665.179 123.322 742.704
202209 601.944 125.298 661.500
202212 570.005 126.098 622.431
202303 582.881 126.953 632.205
202306 529.190 127.663 570.777
202309 630.230 128.151 677.166
202312 403.757 129.395 429.658
202403 556.911 130.607 587.136
202406 494.887 130.792 521.009
202409 706.419 130.361 746.164
202412 555.952 131.432 582.448
202503 480.271 131.948 501.189
202506 591.508 133.241 611.285
202509 745.431 133.819 767.024
202512 862.850 135.271 878.314
202603 631.931 136.539 637.284
202606 774.847 137.695 774.847

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?

Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued. The current stock price of Rp3,900.00 is trading 20.9% below its estimated GF Value™ of Rp4,929.30. GuruFocus considers PT Merck Tbk to be Modestly Undervalued.

Key valuation signals for ISX:MERK:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: Rp4,929.30 vs. price of Rp3,900.00 (20.9% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Merck Tbk Business Description

Address Jalan T.B. Simatupang No. 8, Pasar Rebo, Jakarta Timur, IDN, 13760
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
78GF Score

Get the complete analysis for ISX:MERK

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp3,900.00
Price
Rp4,929.30
GF Value